- Critical Care Symposium to Highlight Biomarkers of AKI Risk
SAN DIEGO, Sept. 24, 2014 /PRNewswire/ -- Medical experts will lead a discussion of modern and useful approaches to managing risk of acute kidney injury (AKI) in certain hospital patients, using the NephroCheck® Test, at a symposium to be held at the 27th annual European Society of Intensive Care Medicine (ESICM) congress in Barcelona on Monday, 29 September from 18:15 to 19:15 local time.
The symposium is sponsored by Astute Medical, which developed the first-of-a-kind NephroCheck® Test. Interested participants are encouraged to visit Astute Medical's booth (55) during the congress.
Dr. Eric Hoste of Ghent University Hospital and Dr. Claudio Ronco of St. Bartolo Hospital will chair the session "AKI Biomarkers: Practical Applications." Investigators will highlight recent clinical studies related to AKI in certain critically ill and post-surgical patients. The distinguished faculty includes, Dr. Azra Bihorac of the University of Florida, Dr Alexander Zarbock of the University of Muenster and Dr. Antonio Artigas, a founding member of ESICM.
The CE-marked NephroCheck® Test is an in vitro diagnostic device that quantitatively measures TIMP-2 (Tissue Inhibitor of Metalloproteinase 2) and IGFBP-7 (Insulin-like Growth Factor Binding Protein 7) proteins associated with kidney function in human urine by fluorescence immunoassay on the Astute140® Meter. The test result is intended to be used in conjunction with clinical evaluation as an aid in the risk assessment of acute kidney injury in the critically ill. The NephroCheck® Test is indicated for prescription use only.
If AKI occurs, costs, length of stay, and the possibility of death can increase.1.2,3
Astute Medical is a sponsor at ESICM, the most prestigious critical care medicine conference in Europe. Throughout the ESICM meeting, Astute Medical representatives will be available at Booth 55 in the main exhibit hall to answer any questions participants may have about the NephroCheck® Test.
About Astute Medical, Inc.
Named by the Wall Street Journal as one of the Top 10 Healthcare Start-Ups of 2012, Astute Medical is dedicated to improving the diagnosis of high-risk medical conditions and diseases through the identification and validation of protein biomarkers that can serve as the basis for novel diagnostic tests. The Company's focus is community and hospital-acquired acute conditions that require rapid diagnosis and risk assessment. Astute Medical's current areas of interest include abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury and sepsis.
For information regarding trademarks and other intellectual property applicable to this product, please see AstuteMedical.com/about/intellectual-property. PN 0337 Rev A 2014/09/15
1 Hobson CE,et al. Cost and Mortality Associated With Postoperative Acute Kidney Injury. Annals of Surgery. 2014;00:1–8
2 Dasta JF, Kane-Gill SL, Durtschi AJ, Pathak DS, Kellum JA. Costs and outcomes of acute kidney injury (AKI) following cardiac surgery. Nephrol Dial Transplant. 2008;23(6):1970-1974.
3 Chertow GM, Burdick E, Honour M, Bonventre JV, and Bates DW. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J. Am. Soc. Nephrol. 16:3365-3370 (2005).
SOURCE Astute Medical, Inc.